JP2005501840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005501840A5 JP2005501840A5 JP2003518546A JP2003518546A JP2005501840A5 JP 2005501840 A5 JP2005501840 A5 JP 2005501840A5 JP 2003518546 A JP2003518546 A JP 2003518546A JP 2003518546 A JP2003518546 A JP 2003518546A JP 2005501840 A5 JP2005501840 A5 JP 2005501840A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- deposit number
- position corresponding
- ugt1a1
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01117608 | 2001-07-23 | ||
| EP02011710 | 2002-05-24 | ||
| PCT/EP2002/008218 WO2003013537A2 (en) | 2001-07-23 | 2002-07-23 | Irinotecan for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005501840A JP2005501840A (ja) | 2005-01-20 |
| JP2005501840A5 true JP2005501840A5 (https=) | 2006-01-05 |
Family
ID=26076655
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518543A Withdrawn JP2005504759A (ja) | 2001-07-23 | 2002-07-23 | Ｃｙｐ３ａ５に基づいたがんの改善治療の手段及び方法 |
| JP2003518545A Withdrawn JP2005505526A (ja) | 2001-07-23 | 2002-07-23 | Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法 |
| JP2003518542A Withdrawn JP2005506971A (ja) | 2001-07-23 | 2002-07-23 | Ｍｒｐ１に基づいたがんの改善治療の手段及び方法 |
| JP2003518546A Withdrawn JP2005501840A (ja) | 2001-07-23 | 2002-07-23 | 癌の改良された治療のための手段および方法 |
| JP2003518544A Withdrawn JP2005508312A (ja) | 2001-07-23 | 2002-07-23 | Ｍｄｒ１に基づいた癌治療の改善のための手段および方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518543A Withdrawn JP2005504759A (ja) | 2001-07-23 | 2002-07-23 | Ｃｙｐ３ａ５に基づいたがんの改善治療の手段及び方法 |
| JP2003518545A Withdrawn JP2005505526A (ja) | 2001-07-23 | 2002-07-23 | Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法 |
| JP2003518542A Withdrawn JP2005506971A (ja) | 2001-07-23 | 2002-07-23 | Ｍｒｐ１に基づいたがんの改善治療の手段及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518544A Withdrawn JP2005508312A (ja) | 2001-07-23 | 2002-07-23 | Ｍｄｒ１に基づいた癌治療の改善のための手段および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050032724A1 (https=) |
| EP (5) | EP1408972A2 (https=) |
| JP (5) | JP2005504759A (https=) |
| AU (5) | AU2002328945A1 (https=) |
| CA (5) | CA2454640A1 (https=) |
| WO (5) | WO2003013534A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4096037B2 (ja) * | 2002-08-12 | 2008-06-04 | 国立大学法人滋賀医科大学 | グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法 |
| US7108992B2 (en) | 2002-11-27 | 2006-09-19 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
| US6916627B2 (en) | 2002-11-27 | 2005-07-12 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
| JP2006526412A (ja) | 2003-05-30 | 2006-11-24 | ユニバーシティ オブ シカゴ | イリノテカン毒性を推定する方法および組成物 |
| JPWO2005028645A1 (ja) * | 2003-09-24 | 2007-11-15 | 株式会社産学連携機構九州 | ＭＤＲ１遺伝子の５’制御領域におけるＳＮＰｓ |
| BRPI0415079A (pt) * | 2003-10-06 | 2006-12-12 | Novartis Ag | biomarcadores para prognóstico de diarréia induzida por droga |
| JP2005245362A (ja) * | 2004-03-05 | 2005-09-15 | Kyowa Medex Co Ltd | 肺癌および頭頸部癌の発症危険率を予測する方法 |
| NZ550430A (en) * | 2004-04-27 | 2009-06-26 | Wellstat Biologics Corp | Cancer treatment using viruses and camptothecins |
| WO2006009805A2 (en) * | 2004-06-18 | 2006-01-26 | Genentech, Inc. | Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors |
| WO2006076288A2 (en) * | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| JP2007060967A (ja) * | 2005-08-30 | 2007-03-15 | Tokyo Institute Of Technology | 遺伝子多型の検出方法および薬物のスクリーニング方法 |
| JP2009515524A (ja) * | 2005-11-10 | 2009-04-16 | アメリカ合衆国 | Ａｂｃｂ１多型バリアントスクリーニング、診断及び処置のための物質及び方法 |
| EP2463365B1 (en) | 2006-11-30 | 2013-09-18 | ARKRAY, Inc. | Probes for detection of UGT1A1 gene, reagent for detection of UGT1A1 gene comprising the same, and uses thereof |
| EP2448406B1 (en) * | 2009-02-26 | 2016-04-20 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
| WO2011031974A1 (en) * | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
| AU2011223883B2 (en) | 2010-03-01 | 2015-10-08 | Cavion, Inc. | Cancer diagnosis and imaging |
| JP2011250726A (ja) * | 2010-06-01 | 2011-12-15 | Toyo Kohan Co Ltd | イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット |
| AU2011281982B2 (en) | 2010-07-20 | 2015-12-17 | Bavarian Nordic A/S | Method for harvesting expression products |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| KR102271848B1 (ko) * | 2013-11-01 | 2021-07-01 | 피트니 파마슈티컬스 피티와이 리미티드 | 암 치료용 약학적 배합물 |
| ES2843829T3 (es) * | 2014-09-26 | 2021-07-20 | Hi Stem Ggmbh Im Deutschen Krebsforschungszentrum Dkfz | Nuevos métodos para la subtipificación y el tratamiento del cáncer |
| JP2016088919A (ja) * | 2014-11-11 | 2016-05-23 | 国立研究開発法人産業技術総合研究所 | イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤 |
| CN107208163B (zh) | 2015-02-17 | 2021-01-08 | 国立大学法人山口大学 | 辅助对伊立替康副作用的发生风险的预测的方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| EP3337467B1 (en) | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| MX385425B (es) | 2015-08-21 | 2025-03-18 | Ipsen Biopharm Ltd | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| CN109939115B (zh) * | 2019-05-06 | 2021-11-02 | 河南中医药大学 | 一种治疗放射性直肠炎的复方栓剂 |
| US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| CN114224875B (zh) * | 2021-11-04 | 2023-08-11 | 中南大学湘雅医院 | 醇类化合物的新用途及抗肿瘤药物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2280855A1 (en) * | 1997-02-27 | 1998-09-03 | Pharmacia & Upjohn Company | Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea |
| BR9916536A (pt) * | 1998-12-23 | 2002-01-02 | Searle & Co | Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação |
| US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
| CA2295429A1 (en) * | 2000-01-06 | 2001-07-06 | Michael Michael | Treatment or prevention of diarrhea |
| EP1251850B1 (en) * | 2000-01-26 | 2006-06-21 | Schering Corporation | Use of a combination preparation in cancer therapy |
| WO2001087306A2 (en) * | 2000-05-15 | 2001-11-22 | Celgene Corp. | Compositions and methods for the treatment of colorectal cancer |
| US20020169141A1 (en) * | 2000-10-06 | 2002-11-14 | Christophe Martin | Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same |
-
2002
- 2002-07-23 AU AU2002328945A patent/AU2002328945A1/en not_active Abandoned
- 2002-07-23 CA CA002454640A patent/CA2454640A1/en not_active Abandoned
- 2002-07-23 CA CA002454643A patent/CA2454643A1/en not_active Abandoned
- 2002-07-23 EP EP02764764A patent/EP1408972A2/en not_active Ceased
- 2002-07-23 EP EP02764763A patent/EP1438050A2/en not_active Withdrawn
- 2002-07-23 AU AU2002331290A patent/AU2002331290A1/en not_active Abandoned
- 2002-07-23 EP EP02767255A patent/EP1408975A2/en not_active Withdrawn
- 2002-07-23 AU AU2002328952A patent/AU2002328952A1/en not_active Abandoned
- 2002-07-23 EP EP02764762A patent/EP1408974A2/en not_active Withdrawn
- 2002-07-23 AU AU2002328950A patent/AU2002328950A1/en not_active Abandoned
- 2002-07-23 CA CA002454637A patent/CA2454637A1/en not_active Abandoned
- 2002-07-23 JP JP2003518543A patent/JP2005504759A/ja not_active Withdrawn
- 2002-07-23 JP JP2003518545A patent/JP2005505526A/ja not_active Withdrawn
- 2002-07-23 WO PCT/EP2002/008219 patent/WO2003013534A2/en not_active Ceased
- 2002-07-23 WO PCT/EP2002/008220 patent/WO2003013535A2/en not_active Ceased
- 2002-07-23 WO PCT/EP2002/008218 patent/WO2003013537A2/en not_active Ceased
- 2002-07-23 EP EP02764757A patent/EP1408973A2/en not_active Withdrawn
- 2002-07-23 JP JP2003518542A patent/JP2005506971A/ja not_active Withdrawn
- 2002-07-23 US US10/484,577 patent/US20050032724A1/en not_active Abandoned
- 2002-07-23 JP JP2003518546A patent/JP2005501840A/ja not_active Withdrawn
- 2002-07-23 AU AU2002328953A patent/AU2002328953A1/en not_active Abandoned
- 2002-07-23 WO PCT/EP2002/008217 patent/WO2003013536A2/en not_active Ceased
- 2002-07-23 CA CA002454648A patent/CA2454648A1/en not_active Abandoned
- 2002-07-23 WO PCT/EP2002/008200 patent/WO2003013533A2/en not_active Ceased
- 2002-07-23 CA CA002454627A patent/CA2454627A1/en not_active Abandoned
- 2002-07-23 JP JP2003518544A patent/JP2005508312A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005501840A5 (https=) | ||
| JP2005505526A5 (https=) | ||
| CN101874120B (zh) | 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型 | |
| DK2471954T3 (en) | Susceptibility genetic variants associated with cardiovascular diseases | |
| AU781437B2 (en) | A novel BAP28 gene and protein | |
| Tammur et al. | Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12 | |
| EP1383927B1 (en) | New polynucleotides and polypeptides of the erythropoietin gene | |
| JP2005506971A5 (https=) | ||
| JPH0759579A (ja) | 腫瘍抑制の遺伝機構 | |
| JP2002325588A (ja) | ヒト・ｄｎａミスマッチ修復蛋白 | |
| KR20140072035A (ko) | 상피세포 성장 인자 수용체 유전자에서의 돌연변이 | |
| Clayton et al. | Tumour suppressor genes in the pathogenesis of human pituitary tumours | |
| AU767378B2 (en) | Polymorphic markers of the LSR gene | |
| CA2376666A1 (en) | Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications | |
| CA2497597A1 (en) | Methods for identifying subjects at risk of melanoma and treatments | |
| Haila et al. | Genomic structure of the human congenital chloride diarrhea (CLD) gene | |
| AU778868B2 (en) | Schizophrenia associated genes, proteins and biallelic markers | |
| JP2004533206A (ja) | 化学療法のための標的としてのガン関連遺伝子 | |
| EP1194545A2 (en) | Secreted polypeptides and corresponding polynucleotides | |
| BRPI0610794A2 (pt) | métodos para diagnosticar uma susceptibilidade a um cáncer e para predizer um risco aumentado de cáncer, kit para ensaiar uma amostra de um indivìduo para detectar uma susceptibilidade a um cáncer, e, métodos para diagnosticar um risco aumentado de cáncer e para diagnosticar um cáncer associado com chr8q24.21 | |
| US20030096952A1 (en) | Novel proteins and nucleic acids encoding same | |
| AU773006B2 (en) | Polymorphic markers of prostate carcinoma tumor antigen-1 (PCTA-1) | |
| CN101671723A (zh) | 人犬尿氨酸酶基因的单核苷酸多态性组成的单倍型 | |
| US6680196B1 (en) | Gene that is amplified and overexpressed in cancer and methods of use thereof | |
| WO2001014550A1 (en) | Prostate cancer-relased gene 3 (pg-3) and biallelic markers thereof |